SEC Company Response from Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Oct 11, 2017
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Oct. 11, 2017 · CIK: 0001512762 · Accession: 0001193125-17-307908
AI Filing Summary & Sentiment
File numbers found in text: 333-220590
Show Raw Text
CORRESP 1 filename1.htm Acceleration Letter Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 October 11, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey Gabor Re: Coherus BioSciences, Inc. Registration Statement on Form S-3 (Registration No. 333-220590) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Coherus BioSciences, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on October 16, 2017, or as soon as practicable thereafter. Thank you for your assistance in this matter. Very truly yours, Coherus BioSciences, Inc. By: /s/ Dennis M. Lanfear Dennis M. Lanfear President and Chief Executive Officer